These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2828071)

  • 41. Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
    Fukuoka M; Negoro S; Masuda N; Kusunoki Y; Matsui K; Ryu S; Takifuji N; Kudoh S; Takada M
    Am J Clin Oncol; 1992 Feb; 15(1):18-22. PubMed ID: 1312768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.
    Kubota K; Furuse K; Kawahara M; Kodama N; Ogawara M; Takada M; Masuda N; Negoro S; Matsui K; Takifuji N; Kudoh S; Kusunoki Y; Fukuoka M
    Cancer Chemother Pharmacol; 1997; 40(6):469-74. PubMed ID: 9332460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
    Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years.
    Gonzalez Baron M; Garcia Giron C; Zamora P; Garcia de Paredes ML; Feliu J; Ordoñez A; Artal A; Garrido P; Chacon JI
    Am J Clin Oncol; 1992 Feb; 15(1):23-8. PubMed ID: 1312769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
    González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM
    Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
    Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
    Nakanishi Y; Takayama K; Kawasaki M; Yatsunami J; Inutsuka S; Wakamatsu K; Tsuruta N; Hara N
    Am J Clin Oncol; 1997 Aug; 20(4):393-7. PubMed ID: 9256897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
    De Marinis F; Rinaldi M; Ardizzoni A; Bruzzi P; Pennucci MC; Portalone L; D'Aprile M; Ripanti P; Romano F; Belli M; Altavilla G; Migliorino MR; Rosso R; Salvati F
    Tumori; 1999; 85(3):177-82. PubMed ID: 10426128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)].
    Nakabayashi T; Miyamoto H; Fujikane T; Shimizu T; Yasuda S; Akita H; Sakai E; Onodera S; Ohsaki Y; Kawakami Y
    Gan To Kagaku Ryoho; 1992 Jan; 19(1):61-7. PubMed ID: 1309633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer.
    Pisters KM; Kris MG; Gralla RJ; Hilaris B; McCormack PM; Bains MS; Martini N
    J Surg Oncol; 1994 Aug; 56(4):236-41. PubMed ID: 8057649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III trial with and without lonidamine in non-small cell lung cancer.
    Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology].
    Kleisbauer JP; Thomas P; Perol M; Taytard A; Poirier R; Collus MJ; Guerin JC; Vergnenegre A; Balmes P; Carles P
    Rev Mal Respir; 1993; 10(4):307-12. PubMed ID: 7694331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
    Ohnoshi T; Hiraki S; Ueoka H; Tamura T; Kawahara S; Yonei T; Yamashita H; Ishii J; Tamai M; Egawa T
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):115-9. PubMed ID: 2827585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluoro-uracil in end-stage head and neck cancer.
    Campbell JB; Dorman EB; McCormick M; Miles J; Morton RP; Rugman F; Stell PM; Stoney PJ; Vaughan ED; Wilson JA
    Acta Otolaryngol; 1987; 103(5-6):519-28. PubMed ID: 3303823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.